InvestorWire NewsRoom


With a Focus On AI and ML Technology, Brain Scientific Inc. (BRSF) Is Positioned to Take The Lead in Growing EEG Market
September 1, 2021

With a Focus On AI and ML Technology, Brain Scientific Inc. (BRSF) Is Positioned to Take The Lead in Growing EEG Market

  • Brain Scientific focused on leveraging AI and ML to detect neurological diseases, aims to create comprehensive database of brain biomarkers to increase diagnosis accuracy
  • Brain Scientific positioned to disrupt EEG market with FDA-cleared patented products that provide cost-effective brain imaging in any setting
  • Current global EEG device market estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026

With more industries embracing artificial intelligence (“AI”) and machine learning (“ML”) than ever before, Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, is ahead of the curve in the neurology market with its development of cost-effective next-generation medical devices and software that aim to leverage AI and ML to improve brain diagnostics in the rapidly growing electroencephalogram (“EEG”) market.

AI generally refers to human-like intelligence capabilities demonstrated by computers, and ML is a subset of AI that refers to algorithms that “learn” through the use of data. Together, they are being used in healthcare to analyze data sets and make treatment predictions that aim to produce better health outcomes. With a similar goal, BRSF aims to leverage AI and ML to improve diagnostic capability with a database of brain biomarkers that collect data on both normal and abnormal brain information. 

Brain Scientific’s use of AI and ML is part of its overall market penetration strategy that includes the development of its patented FDA-cleared NeuroCap(TM) and NeuroEEG(TM) devices. With 22 electrodes and 19 active EEG channels, the NeuroCap — a disposable pre-gelled EEG headset — can be used to record EEGs in nearly any setting. The NeuroCap is complimented by the NeuroEEG — a portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity. Cost-effective, portable, and easily accessible, both devices together are positioned to profoundly shift the market by offering practitioners an affordable way to diagnose brain-related disorders in a range of locations, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes. 

According to Grandview Research, the current global EEG device market was estimated at $956.1 million in 2020 and is expected to reach $1.6 billion revenue by 2026 with an anticipated CAGR of 8.7% between 2019-2026 ( Along with roughly 150 million people diagnosed with epilepsy, dementia and Alzheimer’s disease globally, BRSF is strongly positioned to capture a significant market share of the demand for low-cost imaging devices across the world.

Headquartered in New York, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. were founded in 2015 and went public in 2018. With a focus on developing innovative medical devices and software that disrupt the brain diagnostics market, BRSF is poised to take center stage with solutions that enable medical professionals to cost-effectively diagnose patients with consistency, efficiency and accuracy in virtually any setting.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).